King International Investment to partner with Angeleo Biotechnology on SOD business via Xuzhou Tiantian JV

• King International Investment mapped out a cooperation plan with PRC biotech group Angeleo Biotechnology to develop a superoxide dismutase (SOD) healthcare products business.
• The group agreed to use Xuzhou Tiantian, a former wholly owned unit, as the operating vehicle with registered capital of RMB 5 million.
• Hainan Lucky agreed on Apr. 10, 2026 to transfer 20% of Xuzhou Tiantian to Angeleo for RMB 1 million via an in-kind contribution.
• A shareholders’ agreement signed Jun. 4, 2026 ties both parties’ capital contributions to completion of the planned rights issue.
• Angeleo’s proposed in-kind contribution includes SOD-related intellectual property valued at RMB 1 million in a PRC valuation report dated Jun. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. King International Investment Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254809), on July 23, 2026, and is solely responsible for the information contained therein.